Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|May 22, 2026

The BioPharm Brief: Oncology, Growth, Validation

Today’s BioPharm Brief covers major developments in oncology, rare disease therapeutics, and ADC manufacturing, including positive Phase 3 data for Kelun-Biotech’s sac-TMT in triple-negative breast cancer, promising hypochondroplasia results for vosoritide, and new perspectives on risk-based cleaning validation for highly potent drug manufacturing.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s stories highlight how clinical innovation and manufacturing strategy continue to evolve side by side across the biopharma sector. From positive late-stage oncology and rare disease trial results to growing attention on operational risks tied to highly potent therapies, companies are increasingly balancing scientific advancement with practical commercialization challenges.

First, Kelun-Biotech reported positive Phase 3 results for sacituzumab tirumotecan, or sac-TMT, in first-line metastatic triple-negative breast cancer. The TROP2-directed antibody-drug conjugate demonstrated a statistically significant improvement in progression-free survival compared with chemotherapy. The results are clinically important because triple-negative breast cancer remains one of the most aggressive and difficult-to-treat forms of breast cancer, and the data further reinforce growing momentum behind ADC therapies in solid tumors.

Meanwhile, BioMarin announced that vosoritide met the primary endpoint in a Phase 3 trial evaluating children with hypochondroplasia, a rare genetic growth disorder. According to the company, treatment led to statistically significant improvements in annualized growth velocity. BioMarin plans to submit a supplemental biologics license application to the FDA, potentially expanding the reach of vosoritide beyond achondroplasia into additional skeletal dysplasia indications.

And finally, BioPharm International spoke with industry expert Paul Lopolito about cleaning validation strategies for antibody-drug conjugate manufacturing. As ADC pipelines expand, manufacturers are facing increasing pressure to manage cross-contamination risk, occupational exposure concerns, and regulatory expectations tied to highly potent compounds. Lopolito emphasized that risk-based approaches are becoming essential as facilities adapt to more complex oncology manufacturing environments.


Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • Kelun-Biotech reported positive Phase 3 progression-free survival results for sac-TMT in metastatic triple-negative breast cancer.
  • BioMarin plans an FDA sNDA submission after vosoritide met the primary endpoint in hypochondroplasia.
  • ADC manufacturers are increasingly adopting risk-based cleaning validation strategies for highly potent drug production.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more